VivoSeq
Other

Musculoskeletal

0

Pipeline Programs↗

8

Active Trials↗

2

Companies Involved↗

Musculoskeletal is an early-stage landscape with 0 programs across 2 companies. The most active players are Meda Pharmaceuticals, Primus Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

73/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Meda Pharmaceuticals

0 programs

PreclinicalP

Primus Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

21

clinical trials

Completed8 · 38%
Not yet recruiting3 · 14%
Unknown status2 · 10%
Withdrawn2 · 10%
Active, not recruiting2 · 10%
Recruiting2 · 10%
Other2 · 10%

Clinical Trials

Trial Activity

21 trials

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Recruiting·—·Phase 1·NCT06123286·30 enrolled
Platelet Rich Plasma for Musculoskeletal Conditions
Recruiting·UUniversity of Utah·N/A·NCT07231471·10,000 enrolled
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Active, not recruiting·PPrimus Pharmaceuticals·Phase 4·NCT06157177·50 enrolled
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Active, not recruiting·ECOG-ACRIN Cancer Research Group·N/A·NCT01824836·1,046 enrolled
Impact of Intravenous Iron on Musculoskeletal Function in Older Adults
Not yet recruiting·LLiverpool Hope University·Phase 4·NCT05708170·100 enrolled
Orthobiological Therapies in Musculoskeletal Disorders
Not yet recruiting·PPROREGEN·Phase 1·NCT07434115·300 enrolled
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
Not yet recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07443943·20 enrolled
Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries
Enrolling by invitation·SState University of New York at Buffalo·Phase 4·NCT07393503·60 enrolled
Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma
Completed·UUniversity of Florida·Phase 2·NCT04850222·73 enrolled
Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors
Completed·HHealthPartners Institute·Phase 2·NCT01509079·116 enrolled
Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
Completed·MMeda Pharmaceuticals·Phase 3·NCT00671879·830 enrolled
A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
Completed·MMeda Pharmaceuticals·Phase 3·NCT00671502·840 enrolled
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01194440·63 enrolled
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
Completed·UUniversity of Colorado, Denver·Phase 1·NCT03802552·17 enrolled
Prevention Program for Musculoskeletal Disorders Through Active Pauses for Workers in the Basque Country
Completed·University of the Basque Country (UPV/EHU)·Preclinical·NCT07417527·207 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)